For cT1 renal masses < 4 cm and renal masses < 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress.
Catch up on the top radiology content of the past week.
In a recent interview, Sophia Rose O’Brien, M.D., shared her insights on the roles and limitations of FDG PET/CT and FES PET/CT in the imaging of patients with metastatic breast cancer.
Catch up on the top five most viewed content at Diagnostic Imaging in August 2023.
Catch up on the top radiology content of the past week.
In a recent study examining neuroimaging biomarkers of Alzheimer’s disease, researchers found that neocortical tau pathology exhibited the strongest association with cognitive decline and the use of tau positron emission tomography (tau-PET) provided the best prognostic value of all neuroimaging modalities in this patient population.
Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.
Catch up on the top radiology content of the past week.
Catch up on the most viewed content at Diagnostic imaging in July 2023.
Catch up on the top radiology news of the past week.
In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.
Recognizing the advent of beta amyloid-targeted therapies for the treatment of Alzheimer’s disease, the Centers for Medicare and Medicaid (CMS) has proposed eliminating coverage restrictions that limit amyloid positron emission tomography (PET) scans to clinical trial participants and one amyloid PET scan per lifetime.
The notion of non-physician practitioners (NPPs) attempting to do radiologist-level work is a very slippery slope and what this author refers to as the “bargaining” stage of grief.
In a retrospective review of over 110 million imaging claims for patients with commercial insurance or Medicare Advantage, researchers noted key trends signaling significant increases in imaging billed by non-physician practitioners (NPPs).
Catch up on the top radiology content of the past week.
Carch up on the top radiology content of the past week.
The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?
Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.
A next-generation positron emission tomography/computed tomography (PET/CT) system, Biograph Vision.X, reportedly offers enhanced spatial resolution and a time of flight of 178 picoseconds.
The novel tracer improved both sensitivity and specificity in the study group, of which more than 50 percent were obese and typically more difficult to obtain high-quality imaging.
Kinetic modeling is important to understand how to obtain the best quantitative measurement of novel tracers in the organ of interest.
The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Precision DL, a deep learning-based software which will be available on GE HealthCare’s Omni Legend PET/CT device, reportedly increases the detectability of small, low-contrast lesions by 42 percent.
After five months of exposure to repeated blast events, the majority of nine otherwise healthy military instructors had significantly increased amyloid deposition in the brain, according to positron emission tomography (PET) findings from a new study.
A recent prospective study found that progression-free survival (PFS) and disease-specific survival (DSS) were significantly associated with breast cancer tumor treatment response on 2-(18F)FDG-PET/CT imaging in comparison to contrast-enhanced computed tomography (CT), which showed no evidence of a significant association with tumor response.
